Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What CAGR And Valuation Are Anticipated For The Autoimmune Gastrointestinal Dysmotility Market?

There’s been consistent growth observed in the market size of autoimmune gastrointestinal dysmotility over the past few years. The market is expected to grow from $1.73 billion in 2024 to $1.82 billion in 2025, recording a compound annual growth rate (CAGR) of 5.0%. Several factors contributed to this growth during the historical period, including the rising ignorance about rare diseases, the increase in substandard diagnostic procedures, the surge in cases being incorrectly diagnosed as other gastrointestinal conditions, the growing lack of targeted therapies, and the escalating delays in research progress.

The market for autoimmune gastrointestinal dysmotility is anticipated to experience robust expansion in the upcoming years. It is projected to reach “$2.37 billion by 2029” with a compound annual growth rate (CAGR) of 6.9%. The surge in this prediction period could be linked to the increased incidence of autoimmune diseases, enhancements in diagnostic methods, escalated health care expenditure, an uptick in rare disease registries, and improved education for clinicians. Key trends projected in this timeframe encompass advancements in diagnostic technology, breakthroughs in immunotherapy, cultivation of neurogastroenterology research, advancements in the research and development of motility modulators, and the implementation of personalized treatment strategies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp

What External And Internal Drivers Are Influencing The Autoimmune Gastrointestinal Dysmotility Market?

The increasing occurrence of autoimmune diseases may fuel the expansion of the autoimmune gastrointestinal dysmotility market in the future. Autoimmune diseases are those where the body’s immune system erroneously strikes its healthy cells, tissues, or organs instead of defending them against infections and foreign matter. The upsurge in autoimmune diseases can primarily be attributed to a mix of genetic predisposition and environmental catalysts. These factors collectively disturb the regulation of the immune system and amplify the chance of the body assaulting its own tissues. Autoimmune gastrointestinal dysmotility aids in discovering and handling the underlying autoimmune disorders by exposing immune-mediated damage to the enteric nervous system; it connects gastrointestinal symptoms to systematic autoimmune activities. For example, as per a November 2024 poll by Versorgungsatlas.de, a German organization, nearly 6,304,340 out of 73,241,305 people surveyed in 2022 were identified with at least one autoimmune disease. This led to a crude prevalence rate of 8.61. Hence, the escalating occurrence of autoimmune disorders is promoting the advancement of the autoimmune gastrointestinal dysmotility market.

Which Segment Accounts For The Largest Share In The Autoimmune Gastrointestinal Dysmotility Market?

The autoimmune gastrointestinal dysmotility market covered in this report is segmented –

1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy

2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics

3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs), Celiac Disease

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions

Subsegments:

1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics

2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy

3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals

4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training

Which Long-Term Trends Will Play A Crucial Role In The Autoimmune Gastrointestinal Dysmotility Market?

Prominent firms in the autoimmune gastrointestinal dysmotility market are strategically partnering to offer digital therapy solutions for the management of autoimmune gastrointestinal dysmotility conditions. These alliances increase care for autoimmune gastrointestinal dysmotility by providing combined, virtual-first healthcare with specialist teams, boost symptom control, accessibility to care, and financial efficacy. For example, in March 2022, Solera Health, a digital health corporation from the US, joined forces with Oshi Health, a US-based virtual gastrointestinal care firm, and Vivante Health, another US-based digital health company. This action will bring progressive digital therapy solutions to assist in the administration and treatment of autoimmune gastrointestinal dysmotility. The main goal of this cooperation is to facilitate patient accessibility to specialized care and amplify the overall efficacy of treatment for individuals suffering from gastrointestinal disorders.

Which Companies Hold A Competitive Edge In The 623 Market?

Major companies operating in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/autoimmune-gastrointestinal-dysmotility-global-market-report

Which Region Is Forecasted To Lead The Autoimmune Gastrointestinal Dysmotility Market In The Coming Years?

North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2024. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=24160&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model